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ORIGINAL RESEARCH

Implantable Loop Recorder Monitoring for Reﬁning Management of
Children With Inherited Arrhythmia Syndromes
Jennifer N. Avari Silva, MD, FHRS; Burt I. Bromberg, MD; Fredrick K. Emge, MD; Tammy M. Bowman, CNP; George F. Van Hare, MD, FHRS

Background-—Implantable loop recorders (ILRs) are conventionally utilized to elucidate the mechanism of atypical syncope. The
objective of this study was to assess the impact of these devices on management of pediatric patients with known or suspected
inherited arrhythmia syndromes.
Methods and Results-—A retrospective chart review was undertaken of all pediatric patients with known or suspected inherited
arrhythmia syndromes in whom an ILR was implanted from 2008 to 2015. Captured data included categorization of diagnosis,
treatment, transmitted tracings, and the impact of ILR tracings on management. Transmissions were categorized as symptomatic,
autotriggered, or routine. Actionable transmissions were abnormal tracings that directly resulted in a change of medical or device
therapy. A total of 20 patients met the stated inclusion criteria (long QT syndrome, n=8, catecholaminergic polymorphic ventricular
tachycardia,n=9, Brugada syndrome, n=1, arrhythmogenic right ventricular cardiomyopathy, n=2), with 60% of patients being
genotype positive. Primary indication for implantation of ILR included ongoing monitoring +/ symptoms (n=15, 75%), suspicion of
noncompliance (n=1, 5%), and liberalization of recommended activity restrictions (n=4, 25%). A total of 172 transmissions were
received in patients with inherited arrhythmia syndromes, with 7% yielding actionable data. The majority (52%) of symptom events
were documented in the long QT syndrome population, with only 1 tracing (5%) yielding actionable data. Automatic transmissions
were mostly seen in the catecholaminergic polymorphic ventricular tachycardia cohort (81%), with 21% yielding actionable data.
There was no actionable data in routine transmissions.
Conclusions-—ILRs in patients with suspected or conﬁrmed inherited arrhythmia syndromes may be useful for guiding
management. Findings escalated therapies in 30% of subjects. As importantly, in this high-risk population, the majority of symptom
events represented normal or benign rhythms, reassuring patients and physicians that no further intervention was required. ( J Am
Heart Assoc. 2016;5:e003632 doi:10.1161/JAHA.116.003632)
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O

ver the last 2 decades, considerable progress has been
made in the understanding of primary electrical disorders leading to sudden cardiac death in children and young
adults. Many of these, including long QT syndrome, Brugada
syndrome (BrS), catecholaminergic polymorphic ventricular
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tachycardia (CPVT), and arrhythmogenic right ventricular
cardiomyopathy are autosomal-dominant disorders collectively referred to as the inherited arrhythmia syndromes (IAS).
Despite advancements in the diagnosis and understanding of
IAS, there remain diagnostic uncertainties and management
dilemmas.
Genetic testing can be deﬁnitive when a pathologic
mutation is identiﬁed in a patient with a typical clinical
history. However, the interpretation of mutations is not always
so clear. Speciﬁcally, as genetic testing is being utilized on a
wide scale, variants of unknown signiﬁcance are being
increasingly identiﬁed. Interpreting a novel mutation, or one
not previously linked causally to an IAS, particularly if the
clinical history suggests a low probability of having the
disease, poses a dilemma for the clinician, so-called “genetic
purgatory.”1
After a genetic diagnosis is made for a potentially lethal
inherited arrhythmia, considerable uncertainty remains
regarding the management and outcomes for an individual
Journal of the American Heart Association
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Results
Clinical Patient Data
A total of 20 patients (11 males, 9 females) were implanted
with an ILR for conﬁrmed (n=11, 55%) or suspected (n=9,
45%) IAS: 10 with a Reveal ILR (2008–2013), and 10 with a
LINQ ILR (2014–2015). The average age at time of implant
was 12.53.6 years. Primary indication for implantation of
ILR included ongoing monitoring +/ symptoms (n=15, 75%)
suspicion of noncompliance (n=1, 5%), and liberalization of
guideline-recommended activity restrictions (n=4, 25%).
IAS diagnoses included long QT syndrome (n=8, 40%;
average QTc 466 ms), CPVT (n=9, 45%), arrhythmogenic right
ventricular cardiomyopathy (n=2, 10%), and BrS (n=1, 5%).
Genetic testing yielded 60% (n=9/15) genotype-positive and
40% (n=6/15) genotype-negative patients with no genetic
testing performed in 5 patients. Speciﬁcally, 6 patients had an
identiﬁed pathologic mutation (with 3 of the 6 patients having
compound mutations) and 3 patients with identiﬁed variants
of unknown signiﬁcance (Table 1).

Transmission Data

Methods
After obtaining approval from the Institutional Review Board at
Washington University School of Medicine, a retrospective
chart review was undertaken. Informed consent was waived
per Institutional Review Board approved protocol. Patients
who underwent ILR implantation with a known or suspected
diagnosis of an IAS from 2008 to 2015 were identiﬁed. IAS
diagnoses in this analysis included long QT syndrome, CPVT,
BrS, and arrhythmogenic right ventricular cardiomyopathy.
Patients who were not known or suspected IAS patients were
not included in the analysis. Data collected included categorization of diagnosis, treatment, transmitted tracings, and the
impact of the ILR on patient management. Transmissions
were categorized as symptomatic (patient triggered), autotriggered (device triggered), or routine, though transmission
could fall into >1 category. Transmission data were categorized as “actionable” if the arrhythmia detected led directly to
a change of medical or device therapy. Patient-speciﬁc
programming of tachycardia and bradycardia zones was
performed at time of implant, taking into account patient
age, medications, and previous documented arrhythmia data
(when available).

Statistical Analysis
Results are predominantly descriptive ﬁndings and expressed
as percentages, with mean values (and SD) for continuous
variables.
DOI: 10.1161/JAHA.116.003632

A total of 172 total transmissions were received, with an
average of 8.67 ILR downloads/patient. There were 12
transmissions (7%) yielding actionable data in 6 patients.
(Table 2).
In the LQT group, there were 58 total transmissions
(actionable data n=1, or 2%), in the CPVT group there were
100 transmissions (actionable data n=10, or 10%), in the
arrhythmogenic right ventricular cardiomyopathy group there
were 8 transmissions (actionable data n=1, or 13%) and lastly,
in the BrS group there were 6 transmissions (actionable data
n=0) (Table 2). The majority of actionable events, 10/12
(83%), occurred in patients with a diagnosis of CPVT.
A total of 33 transmissions were labeled by patients as
symptom episodes, including chest pain, syncope, dizziness,
palpitations, nausea, and seizure. Of the 33 symptom events,
3 (10%) had an actionable tracing resulting in change of
medication or device with the remaining 30 transmissions
(90%) demonstrating sinus rhythm/sinus tachycardia +/
premature ventricular contractions. Additionally, 42 automatic
transmissions were received with 8 (19%) transmissions
demonstrating actionable data, predominantly in the CPVT
population. The remaining 34 automatic transmissions (81%)
demonstrated sinus rhythm/sinus tachycardia and occasionally isolated premature ventricular contractions. Nine transmissions were identiﬁed as both symptom and automatic
transmissions, with 1 of these transmissions (11%) yielding
actionable data. Eighty-eight routine transmissions were
downloaded with no actionable data in those transmissions
(Figure; Table S1).
Journal of the American Heart Association
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patient. There is general agreement that a subpopulation of
phenotype-positive IAS patients (speciﬁcally long QT syndrome and CPVT patients) should receive b-blocker therapy.
However, clinicians must exercise clinical judgment when
negotiating activity restrictions while taking into account
guidelines for sports participation.2–5
The use of implantable loop recorders (ILRs) has been
reported in pediatric patients with infrequent syncope or
palpitations.6–8 In 2011, Kubala et al9 published their experience with the use of ILRs in 11 BrS patients where there was
clinical suspicion of ventricular arrhythmias. They identiﬁed
bradycardia and atrioventricular block during syncopal
episodes, but no ventricular arrhythmias.
In an effort to identify occult arrhythmias, as well as to
accurately assess cardiac rhythms during symptomatic
events, we have implanted ILRs in selected patients with a
documented or suspicious history for IAS. The intent of this
study is to categorize the ﬁndings of continuous ILR
monitoring and the impact it had on tailoring the management
of potentially life-threatening arrhythmias to individual
patients.

ILR in Pediatric IAS
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Table 1. Clinical Patient Data, Including Genetics, Indications for ILR, and Medical Therapy

Patient

Clinical
Diagnosis

Age at
Implant (y)

Genetic Test Results

Medical Therapy

1

LQTS

15.9

Negative

None

2

LQTS

4.8

n/a

None

3

LQTS

16.1

Negative

Betaxolol

4

LQTS

11.7

Pathogenic mutation: KCNQ1—Ser566Phe
VUS: SNTA1—Arg336Trp

Nadolol

5

LQTS

10.7

Pathogenic mutation: KCNQ1—Arg366Trp

Nadolol

6

LQTS

7.9

Negative

None

7

LQTS

12

Negative

Nadolol

8

LQTS

13

VUS: KCNH2—Ala913Val

None

9

CPVT

18.3

n/a

Noncompliant

10

CPVT

10.6

n/a

Noncompliant

11

CPVT

13.2

VUS: RYR2—c.1465+4C>T, IVS15+4C>T

Nadolol

12

CPVT

17.3

Negative

Atenolol

13

CPVT

7.8

Pathogenic mutation: RYR2—Glu3987Lys

Nadolol

14

CPVT

13.6

Pathogenic mutation: RYR2—Arg4959Gln

Atenolol

15

CPVT

13.1

VUS: CACNA1C—Ile1323Ile
VUS: CACNA1C—Ala68Thr
VUS: HCN4—Val451Met

Nadolol

16

CPVT

13.2

Pathogenic mutation: KNCJ2—p.R218Q
Pathogenic mutation: SCN5A—p.T1304M
Benign mutation: AKAP9

Nadolol+flecainide

17

CPVT

10.5

n/a

Nadolol

18

ARVC

14.7

VUS: RYR2—Arg1013Gln

Atenolol

19

ARVC

17.9

n/a

None

20

BrS

7.6

Negative

None

Patient data, including demographic data, clinical data, genetic diagnoses, indications for implant, and medical therapy are presented. ARVC indicates arrhythmogenic right ventricular
cardiomyopathy; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ILR, implantable loop recorders; LQTS, long QT syndrome; n/a, not applicable;
VUS, variant of unknown signiﬁcance.

Outcomes/Current Status
There were no deaths in the patient cohort. At last follow-up,
ILRs were explanted in 6/20 (30%) of patients for device end of
life. A single patient with CPVT had the ILR upgraded to an
implantable cardioverter deﬁbrillator for symptomatic polymorphic ventricular tachycardia. There were no adverse events
associated with the device, including infection or erosion.

Discussion
This study represents the only study to date investigating the
utility of ILRs in pediatric patients across all inherited
arrhythmia syndromes. There are several novel ﬁndings from
this study. First, symptoms in this patient population do not
correlate well with arrhythmic events. Additionally, automatic
transmissions were important in detecting subclinical
DOI: 10.1161/JAHA.116.003632

arrhythmias. These data inﬂuenced clinical decision making
regarding medication titration, addition of medication, medication compliance, and titrating activity levels. Lastly, variants of unknown signiﬁcance need to be interpreted carefully
in the context of the clinical picture and clinician index of
suspicion, which are important in guiding decision making.
Important implications arise from these ﬁndings. The long
QT syndrome patient cohort had the largest number of
symptoms transmissions (19 symptoms +/
automatic
transmissions/34 total transmissions, 56%) with only 1
symptom tracing (5%) leading to titration in medication
regimen. The remaining 95% of symptom events in the long
QT population were not associated with arrhythmia. Through
the entire cohort of patients, 90% of symptomatic transmissions demonstrated normal sinus rhythm/sinus tachycardia
(74%) or minimal rhythm abnormalities such as isolated
premature ventricular contractions (16%). Given that the
Journal of the American Heart Association
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Table 2. Symptom and Actionable Transmission Data by Patient

Patient

Clinical
Diagnosis

Actionable
Data (No.
Transmissions)

If Actionable Data, What Was
Rhythm and Resultant Action?

Symptom Events
(No. Transmissions)

If Symptom Event, What
Was the Rhythm?

1

LQTS

None

n/a

Yes (3)

NSR92; ST

2

LQTS

None

n/a

Yes (1)

ST

3

LQTS

None

n/a

Yes (6)

ST96

4

LQTS

None

n/a

Yes (2)

ST92

5

LQTS

None

n/a

Yes (5)

NSR95

6

LQTS

None

n/a

None

n/a

7

LQTS

None

n/a

None

n/a

8

LQTS

Yes (1)

Tightly coupled ventricular couplet→Activity
Restrictions

Yes (2)

ST; Tightly coupled ventricular couplet

9

CPVT

None

n/a

Yes (6)

ST93; NSR w/ventricular bigeminy;
ST w/isolated PVCs92

10

CPVT

None

n/a

Yes (2)

ST92

11

CPVT

None

n/a

Yes (1)

ST

12

CPVT

None

n/a

Yes (1)

ST

13

CPVT

Yes (2)

Polymorphic VT→Initiate of b-blocker
AT→Uptitrate of b-blocker

None

n/a

14

CPVT

Yes (4)

Sinus pauses, bidirectional ventricular coupletsaInitiate
atenolol
Nonsustained VT→Encourage medication compliance
Significant sinus pauses→Wean b-blockers
Polymorphic VT→Explant ILR; Implant ICD

Yes (1)

TdP

15

CPVT

Yes (1)

Multifocal PVCs→Initiate nadolol

Yes (2)

ST; NSR w/ventricular trigeminy

16

CPVT

Yes (3)

Multifocal PVCs→Uptitrate nadolol
Bidirectional VT→Initiate Flecainide
Bidirectional Ventricular CoupletsaUptitrate flecainide

Yes (4)

Bidirectional VT; NSR w/ventricular
bigeminy92; NSR w/isolated PVCs

17

CPVT

None

n/a

None

n/a

18

ARVC

Yes (1)

Sinus pause→Wean b-blocker

Yes (1)

ST

19

ARVC

None

n/a

Yes (1)

ST

20

BrS

None

n/a

Yes (4)

ST93; NSR

Both symptom and actionable data by patent are presented. Details about transmission data are provided. ARVC indicates arrhythmogenic right ventricular cardiomyopathy; AT, atrial
tachycardia; BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter deﬁbrillator; ILR, ; LQTS, long QT syndrome; n/a, not
applicable; NSR, normal sinus rhythm; PVCs, premature ventricular contractions; ST, sinus tachycardia; TdP, Torsades de Pointes; VT, ventricular tachycardia.

majority of symptom-driven transmissions were not actionable or lethal arrhythmias, symptoms are not reliable markers
for escalation of therapy or guidance around activity. Current
practices when caring for these children often includes
incorporating symptoms into risk stratiﬁcation algorithms. ILR
data demonstrate that symptoms in this population may not
be reliable surrogates for arrhythmia.
Identiﬁcation of occult arrhythmias is crucial to optimal
management of patients with known or suspected IAS. In fact,
19% of automatically recorded transmission contained data
that altered the patients’ medical course. Prior to the growing
use of ILRs in this population, the incidence of subclinical
arrhythmias in the IAS population was unknown. Perhaps
DOI: 10.1161/JAHA.116.003632

most concerning was the data collected from the CPVT
cohort, where 21% of automatic transmissions yielded
actionable data, implying signiﬁcant subclinical arrhythmia
prevalence in this population. Intelligent programming of the
ILR in this subpopulation is important in identifying these
occult arrhythmic events.
Patients with genetic mutations classiﬁed as variants of
unknown signiﬁcance are a growing clinical conundrum. In the
cohort presented, 5 patients had genetic variants of unknown
signiﬁcance with 3/5 patients (60%) having actionable
tracings. For patients with a documented variant of unknown
signiﬁcance, demonstration of polymorphic ventricular tachycardia would swing the pendulum in the direction of
Journal of the American Heart Association
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A

Figure. The tracings shown were obtained from 4 different patients in the cohort. The tracing in (A) represents an ILR download from a patient
with genotype-positive catecholaminergic polymorphic ventricular tachycardia (CPVT). This event of polymorphic ventricular tachycardia
occurred with activity (running), but the patient was asymptomatic with this event. In response to this event, the patient was started on nadolol.
B, Represents a symptom event (chest pain) from a patient being treated with nadolol with genotype-positive CPVT. The tracing demonstrates
ventricular bigeminy followed by a bidirectional ventricular tachycardia, which then spontaneously terminates and returns to sinus rhythm with
ventricular bigeminy. In response to this event, the patient was admitted for initiation of ﬂecainide in addition to nadolol. C, Represents a patient
with genotype-positive CPVT who had a symptom event and a history of noncompliance with medication. This event of polymorphic ventricular
tachycardia occurred during a time of emotional stress. Following this download, the patient underwent implantation of an automatic
intracardiac deﬁbrillator. The patient tracing in (D) is from a symptom event (chest pain, near syncope) in a patient with long QT syndrome who
had just been jogging. He was being treated with betaxolol and was compliant with this medication. The tracing demonstrating sinus rhythm was
reassuring that there was not an arrhythmic component to his symptoms. ILR indicates implantable loop recorder.
heightened individual treatment as well as cascade screening
of at-risk family members. These data give credence to clinical
index of suspicion weighing heavily in clinical decision
making.
DOI: 10.1161/JAHA.116.003632

Guidance around activity is an important part of the
ongoing management for these patients. In this cohort, ILRs
provided important data to guide in titration of activity level
with an acceptable level of risk. After shared decision making
Journal of the American Heart Association
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Study Limitations
This study, despite spanning 7 years, is limited by a small
sample size and therefore it is difﬁcult to draw statistically
signiﬁcant conclusions. Additionally, this is a retrospective
study design and is therefore has the associated biases of
retrospective studies. There are inherent limitations in data
collection, given programming limitations. Our practice has
been to tailor these parameters to be patient speciﬁc, taking
into account age, activity level, medications, and prior
arrhythmic data (when available). However, it is possible that
patients may experience ectopy that is slower or shorter than
the programmed tachycardia zone, which would therefore not
be recorded.

Conclusions
ILRs in patients with suspected or conﬁrmed IAS may be
useful for guiding management. Findings escalated therapies

DOI: 10.1161/JAHA.116.003632

in 30% of subjects. As importantly, in this high-risk population,
the majority of symptom events represented normal or benign
rhythms, reassuring patients and physicians that no further
intervention was required. Given the wealth of data ILRs
provide in these patients, perhaps ILRs should be considered
in all IAS patients who do not meet criteria for implantable
cardioverter deﬁbrillators, particularly the CPVT subgroup.

Disclosures
None.

References
1. Ackerman MJ. Genetic purgatory and the cardiac channelopathies: exposing
the variants of uncertain/unknown signiﬁcance issue. Heart Rhythm.
2015;12:2325–2331.
2. Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson
JE, Deal BJ, Driscoll DJ, Estes NA III, Araujo CG, Liang DH, Mitten MJ, Myerburg
RJ, Pelliccia A, Thompson PD, Towbin JA, Van Camp SP; Working Groups of the
American Heart Association Committee on Exercise CR, Prevention, Councils
on Clinical C and Cardiovascular Disease in the Y. Recommendations for
physical activity and recreational sports participation for young patients with
genetic cardiovascular diseases. Circulation. 2004;109:2807–2816.
3. Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive
athletes with cardiovascular abnormalities—general considerations. J Am Coll
Cardiol. 2005;45:1318–1321.
4. Pelliccia A, Zipes DP, Maron BJ. Bethesda Conference #36 and the European
Society of Cardiology Consensus Recommendations revisited: a comparison of
U.S. and European criteria for eligibility and disqualiﬁcation of competitive
athletes with cardiovascular abnormalities. J Am Coll Cardiol. 2008;52:1990–
1996.
5. Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ. Eligibility and disqualiﬁcation
recommendations for competitive athletes with cardiovascular abnormalities:
task force 10: the cardiac channelopathies: a scientiﬁc statement from the
American Heart Association and American College of Cardiology. J Am Coll
Cardiol. 2015;66:2424–2428.
6. Frangini PA, Cecchin F, Jordao L, Martuscello M, Alexander ME, Triedman JK,
Walsh EP, Berul CI. How revealing are insertable loop recorders in pediatrics?
Pacing Clin Electrophysiol. 2008;31:338–343.
7. Ergul Y, Tanidir IC, Ozyilmaz I, Akdeniz C, Tuzcu V. Evaluation rhythm problems
in unexplained syncope etiology with implantable loop recorder. Pediatr Int.
2015;57:359–366.
8. Al Dhahri KN, Potts JE, Chiu CC, Hamilton RM, Sanatani S. Are implantable
loop recorders useful in detecting arrhythmias in children with unexplained
syncope? Pacing Clin Electrophysiol. 2009;32:1422–1427.
9. Kubala M, Aissou L, Traulle S, Gugenheim AL, Hermida JS. Use of implantable
loop recorders in patients with Brugada syndrome and suspected risk of
ventricular arrhythmia. Europace. 2012;14:898–902.
10. Tomson TT, Passman R. The reveal LINQ insertable cardiac monitor. Expert Rev
Med Devices. 2015;12:7–18.

Journal of the American Heart Association

Downloaded from http://jaha.ahajournals.org/ at Washington University on June 8, 2016

6

ORIGINAL RESEARCH

between clinician, patient, and family, and frank conversations
about risk, certain patients had liberalized activity guidance
with close monitoring by ILR with no documented arrhythmic
events. ILRs may be useful in allowing select patients to
reenter sports with intensive arrhythmia monitoring.
Lastly, 6/20 monitored patients (30%) had arrhythmias
identiﬁed that prompted interventions including activity
restriction, titration of medication, and implantable cardioverter deﬁbrillator implant. These data, which are critically
important in guiding patients regarding medical/device therapy and activity restrictions, are increasingly available due to
the increased use of ILRs, likely due to lower threshold for
implantation. In fact, the newer generation LINQ ILR has the
advantage of being markedly (87%) smaller than the previous
generation as well as being quickly inserted subcutaneously,
thereby lowering the clinician’s threshold to recommend the
device.10 Our data support this trend as equal numbers of
devices (n=10) were implanted in the 5 years of the Reveal
device versus 2 years of the LINQ.
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Substrate

# of transmissions

Symptom
transmissions

Automatic
transmissions

Routine
transmissions

LQTS

Total, n=58

12

5

34

Actionable transmissions, n=1

1

0

0

Total, n=100

17

34

49

Actionable transmissions, n=10

3

7

0

Total, n=8

2

3

3

Actionable transmissions, n=1

0

1

0

Total, n=6

4

0

2

Actionable transmissions, n=0

0

0

0

Total transmissions

42

42

88

Actionable transmissions, n=12

4

8

0

CPVT

ARVD

BrS

Total
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Table S1:
Number of symptom, automatic and routine standard of
care transmissions by disease substrate. CPVT =
Catecholaminergic polymorphic ventricular tachycardia,
LQTS = Long QT syndrome, BrS = Brugada syndrome,
and ARVC = Arrhythmogenic right ventricular
cardiomyopathy.
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